Esophageal Cancer Clinical Trial
Official title:
Randomized, Double-Blinded Phase II Trial of Esomeprazole Versus Esomeprazole + Two Doses of Aspirin in Barrett's Esophagus Patients
This randomized phase II trial is studying the effect of esomeprazole magnesium and aspirin on tissue PGE2 levels compared with esomeprazole and placebo. This type of chemoprevention treatment investigates the use of certain drugs to assess whether they assist in the prevention of cancer. The use of esomeprazole magnesium with or without aspirin may help prevent esophageal cancer in patients with Barrett esophagus.
PRIMARY OBJECTIVES:
I. To assess the effects of a 28 day intervention with aspirin 81 mg placebo orally (PO)
once daily (QD) + aspirin 325 mg placebo PO QD + esomeprazole 40 mg PO BID versus aspirin 81
mg PO QD + aspirin 325 mg placebo PO QD + esomeprazole 40 mg PO BID versus aspirin 325 mg PO
QD + aspirin 81 mg placebo PO QD + esomeprazole 40 mg PO BID on the absolute change in
tissue prostaglandin E2 (PGE2) concentration, as determined from Barrett's esophagus mucosal
biopsy samples obtained pre- and post-intervention (i.e. two pair-wise comparisons of two
different doses of active aspirin regimens versus aspirin placebo group), Specifically, the
two active aspirin + esomeprazole arms will be independently analyzed to see if they
significantly reduce the mean tissue PGE2 concentration from Pre- to Post-intervention as
compared to the aspirin placebo + esomeprazole arm.
SECONDARY OBJECTIVES:
I. To determine if the change in the tissue PGE2 concentration decreases significantly in
the aspirin placebo + esomeprazole arm.
II. To compare the change in mean tissue PGE2 concentration between the two active
intervention arms to determine which one appears the most promising for further testing.
III. To assess the effects of the three agents (arms) with respect to proliferation (Ki-67),
apoptosis (caspase-3 expression), COX-2 expression, and p16 methylation using Pre- and
Post-Intervention biopsy samples obtained from Barrett's mucosal tissue.
IV. To evaluate all adverse events associated with each of the three intervention arms.
V. To provide exploratory summaries of PGE2 concentration values by patient subgroups of
interest.
VI. To provide descriptive summaries of the esophagogastroduodenoscopy (EGD) results, the
rate of dysplasia, adverse events, and the Run-In Agent compliance on all participants that
signed a consent form and started the Run-In phase of the trial.
VII. To establish a biospecimen repository archive for future correlative studies.
OUTLINE: This is a multicenter, randomized, double-blind, placebo-controlled study. Patients
are stratified according to dysplasia status, gender, and length of Barrett segment of
circumferential involvement (5 cm vs = 5 cm). Patients are randomized to 1 of 3 treatment
arms.
ARM I: Patients receive two oral placebos once daily and oral esomeprazole magnesium twice
daily.
ARM II: Patients receive oral acetylsalicylic acid (aspirin) and oral placebo once daily and
oral esomeprazole magnesium twice daily.
ARM III: Patients receive a higher-dose of oral aspirin (higher than in arm II) and a
lower-dose of oral placebo (lower than in arm II) once daily and oral esomeprazole magnesium
twice daily.
In all arms, treatment continues for 28 days in the absence of unacceptable toxicity. Tissue
samples are collected before and after treatment and examined for tissue-based biomarkers
(i.e., PGE_2, Ki-67, caspase-3 apoptosis, and cyclooxygenase-2) by immunohistochemistry,
enzyme immunoassay, Western blot, and polymerase chain reaction.
After completion of study therapy, patients are followed 7 - 30 days.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02544737 -
Apatinib for Metastatic Esophageal Cancer.
|
Phase 2 |